Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that exhibits antiviral and anticancer activities. Efavirenz is clinically used to treat HIV infection; it induces autophagy in neurons, leading to some centrally mediated toxicity. In various cancer cell lines, efavirenz inhibits cellular proliferation and increases activation of p53.
| Cas No. | 154598-52-4 |
|---|---|
| Purity | ≥99% |
| Formula | C14H9ClF3NO2 |
| Formula Wt. | 315.67 |
| IUPAC Name | (4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-1H-3,1-benzoxazin-2-one |
| Melting Point | 139-141°C |
| Solubility | Ethanol (20 mg/ml), DMF (20 mg/ml), DMSO (14 mg/ml) |
| Appearance | White to off white powder |
| Store Temp | Ambient |
|---|---|
| Ship Temp | Ambient |
| MSDS | |
|---|---|
| Info Sheet | |
| Brochures |
Schauer GD, Huber KD, Leuba SH, et al. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence. Nucleic Acids Res. 2015 Feb 1;42(18):11687-96. PMID: 25232099.
Purnell PR, Fox HS. Efavirenz induces neuronal autophagy and mitochondrial alterations. J Pharmacol Exp Ther. 2014 Nov;351(2):250-8. PMID: 25161171.
Hecht M, Harrer T, Büttner M, et al. Cytotoxic effect of efavirenz is selective against cancer cells and associated with the cannabinoid system. AIDS. 2013 Aug 24;27(13):2031-40. PMID: 23612009.
